Prognostic Value of Lactate Levels in Patients With STEMI Undergoing Primary PCI

Prognostic Value of Systemic Arterial Lactate Levels in Patients With ST-segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05503329

Enrollment

300

Registered

2022-08-16

Start date

2022-01-25

Completion date

2022-06-30

Last updated

2022-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

STEMI

Brief summary

To assess the prognostic value of systemic arterial lactate levels in patients with ST segment elevation myocardial infarction undergoing primary PCI and correlate with the results of primary PCI and 30 days MACE follow up.

Detailed description

* Study Population: STEMI patients treated with primary PCI. * Study period: over 6 months. * Sample Size: 300 patients. All patients received the standard care for acute STEMI patients which is the primary percutaneous intervention in addition to medications. Hyperlactemia is defined as elevated lactic acid level in the blood. The normal blood lactate level is (0.5-1 mmol/L). All subjects were subjected to 1. Careful history taking 2. Full cardiac examination 3. Investigations include: 1. 12 lead surface ECG. 2. Lactate level and full labs 3. Pre-discharge echocardiography 4. Peri-procedural details of primary PCI the investigators assessed the relation between hyperlactemia and coronary flow, peak cardiac enzymes, hemodynamic parameters and MACE in 30 days follow up

Interventions

DIAGNOSTIC_TESTarterial lactate level

an arterial lactate level measured from arterial sample from STEMI patients

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patient with ST-segment elevation myocardial infarction for the first time. * Patients undergoing primary PCI. * Adult patients ≥ 18 years old.

Exclusion criteria

* Hemodynamically unstable patients. * Patients with renal impairment (creatinine clearance \< 30 ml/min). * Patients who developed flow limiting coronary dissection or mechanical complication during the procedure. * Patients presenting \> 24 hours after symptoms onset.

Design outcomes

Primary

Measure	Time frame	Description
Major adverse caediac events	30 days	we follow up occurrence of death, reinfarction, repeated hospitalization and new onset heart failure

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026